Rybelsus is an oral medication manufactured by Novo Nordisk to help people control their blood sugar, insulin levels, and appetite. It was approved by the US Food and Drugs Administration (FDA) in September 2019. Since then, it’s been a common prescription for people dealing with type 2 diabetes.
Unlike the two other popular semaglutide drugs by Novo Nordisk, Ozempic, and Wegovy, Rybelsus is taken orally on a daily basis. It comes in doses as low as 3 mg and as high as 14 mg. It’s taken on an empty stomach 30 minutes before eating.
It has semaglutide, which acts as a glucagon-like peptide-1 (GLP-1) agonist. It’s the first and only GLP-1 receptor agonist, making it a prolific development by Novo Nordisk.
The most common side effects of Rybelsus are diarrhea, vomiting, nausea, and appetite loss. During the Digestive Disease Week Conference in 2024, scientists claimed that GLP-1 and its side effects could eventually lead to gastroparesis, which is defined as the slowing down of your stomach’s digestion. It’s an untreatable condition that can result in more health problems in the future.
Rybelsus is a popular type 2 diabetes treatment because it's taken orally. If you or a relative are now dealing with gastroparesis, we encourage you to reach out to our team to see if you are eligible to file a Rybelsus claim. Make sure you meet these eligibility criteria:
Please prepare your medical records and any proof that you’ve been treated with Rybelsus.
The number of lawsuits against Novo Nordisk and GLP-1 is increasing. Between December 2024 and February 2025, there have been 143 new lawsuits filed. Plaintiffs have noted that the medications in question include Rybelsus, Ozempic, and Wegovy.
Our legal team can help you become a part of a bigger movement against GLP-1 drugs. Aside from holding companies like Novo Nordisk accountable, the claim will also help you get compensation for the related health problems you or your relatives are now facing.